Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al

Ann Rheum Dis. 2021 May;80(5):e76. doi: 10.1136/annrheumdis-2020-218175. Epub 2020 Jun 19.

Authors

Vasco C Romão^{1

2}, Ana Rita Cruz-Machado^{1

2}, João Eurico Fonseca^{3

2}

Affiliations

¹ Rheumatology Department, Hospital de Santa Maria, CHULN, Lisbon Academic Medical Centre, Lisbon, Portugal.
² Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
³ Rheumatology Department, Hospital de Santa Maria, CHULN, Lisbon Academic Medical Centre, Lisbon, Portugal jecfonseca@gmail.com.

PMID: 32561609
DOI: 10.1136/annrheumdis-2020-218175

No abstract available

Keywords: arthritis, rheumatoid; epidemiology; hydroxychloroquine; lupus erythematosus, systemic.

Publication types

Letter
Comment

MeSH terms

Antimalarials* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
COVID-19*
Humans
Hydroxychloroquine / therapeutic use
SARS-CoV-2

Substances

Antimalarials
Hydroxychloroquine